Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study

Figures & data

Table 1 Patient characteristics and baseline arterial blood gas

Age (years)	FEV1 (L)	FiO2	pH	PaCO2 (mmHg)	HCO3^− (mmHg)	PaO2 (mmHg)
81±4.1	1.16±0.18	0.33±0.07	7.44±0.06	27.9±5.4	18.8±5.9	104.2±19.6

Note: Data are presented as mean ± SD.

Abbreviations: FEV₁, force expiratory volume in 1 second; FiO₂, fractional concentration of inspired oxygen; PaCO₂, partial pressure of arterial carbon dioxide; PaO₂, partial pressure of arterial oxygen; SD, standard deviation.

Table 2 Lung mechanics before and up to 3 hours after salmeterol/fluticasone inhalation

Parameters for lung mechanics	Baseline	30 minutes	1 hour	2 hours	3 hours
Rrs (cm H2O/L/s)	17.4±7.6	16.3±7.4a	15.8±7.4a	14.9±6.7a	16.4±7.6
Crs, st (mL/cm H2O)	46.0±23.6	45.3±23.5	45.0±23.7	45.2±23.7	45.3±23.8
PIP (cm H2O)	29.8±7.6	26.4±6.1a	24.3±5.6a	23.9±5.8a	27.2±7.8a
Pplat (cm H2O)	23.1±10.2	21.2±7.1	19.9±5.0	21.7±5.5	23.5±9.9
MAP (cm H2O)	12.3±3.4	12.2±3.5	11.3±3.2a	10.9±3.2a	11.4±3.5
PaO2/FiO2	328.0±83.8	NA	374.7±97.8	NA	331.3±87.8

Notes: Values are presented as mean ± SD.

a Significantly different from baseline values (P<0.05, Wilcoxon signed rank test).

Abbreviations: Crs, st, end-inspiratory static compliance of the respiratory system; MAP, mean airway pressure; NA, not applicable; PaO₂/FiO₂, partial pressure of oxygen in arterial blood/fraction concentration of inspired oxygen; PIP, peak inspiratory pressure; Pplat, plateau pressure; Rrs, maximum resistance of the respiratory system; SD, standard deviation.

Figure 1 Percent changes (Δ-difference %) in peak inspiratory pressure (PIP), mean airway pressure (MAP), and maximum resistance of the respiratory system (Rrs).

Note: Changes were observed after the use of combination therapy with salmeterol/fluticasone inhalation.

Figure 2 Individual patient values of maximum resistance of the respiratory system (Rrs).

Note: Reduction in airway resistance was observed 30 minutes after salmeterol/fluticasone treatment.

Figure 3 Effect of combination therapy with salmeterol/fluticasone inhalation on maximum resistance of the respiratory system (Rrs) mean values.

Notes: Mean values ± SD of airway resistance at baseline and up to 3 hours. *Significantly different from baseline values (P<0.05, Wilcoxon signed rank test).
Abbreviation: SD, standard deviation.

Figure 4 Effect of combination therapy with salmeterol/fluticasone inhalation on peak inspiratory pressure mean values.

Notes: Mean values ± SD of peak inspiratory pressure at baseline and up to 3 hours. *Significantly different from baseline values (P<0.05, Wilcoxon signed rank test).
Abbreviations: SD, standard deviation; PIP, peak inspiratory pressure.

Figure 5 Effect of combination therapy with salmeterol/fluticasone inhalation on PaO₂/FiO₂ mean values.

Note: Mean values ± SD of mean PaO₂/FiO₂ at baseline and up to 3 hours.
Abbreviations: PaO₂/FiO₂, partial pressure of oxygen in arterial blood/fraction concentration of inspired oxygen; SD, standard deviation.